| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50242-599-01 | 50242-599 | HUMAN PRESCRIPTION DRUG | Xofluza | Baloxavir Marboxil | GRANULE, FOR SUSPENSION | ORAL | 20250530 | N/A | NDA | NDA214410 | Genentech, Inc. | BALOXAVIR MARBOXIL | 30 mg/1 | 1 PACKET in 1 CARTON (50242-599-01) / 1 GRANULE, FOR SUSPENSION in 1 PACKET |
| 50242-617-01 | 50242-617 | HUMAN PRESCRIPTION DRUG | Xofluza | Baloxavir Marboxil | GRANULE, FOR SUSPENSION | ORAL | 20250530 | N/A | NDA | NDA214410 | Genentech, Inc. | BALOXAVIR MARBOXIL | 40 mg/1 | 1 PACKET in 1 CARTON (50242-617-01) / 1 GRANULE, FOR SUSPENSION in 1 PACKET |
| 50242-583-01 | 50242-583 | HUMAN PRESCRIPTION DRUG | Xofluza | BALOXAVIR MARBOXIL | GRANULE, FOR SOLUTION | ORAL | 20201123 | N/A | NDA | NDA214410 | Genentech, Inc. | BALOXAVIR MARBOXIL | 40 mg/20mL | 1 BOTTLE, GLASS in 1 CARTON (50242-583-01) / 20 mL in 1 BOTTLE, GLASS |